Introduction：Basic information about CAS 163133-43-5|Naproxcinod, including its chemical name, molecular formula, synonyms, physicochemical properties, and safety information, etc.
| Common Name | Naproxcinod |
|---|
| CAS Number | 163133-43-5 | Molecular Weight | 347.36200 |
|---|
| Density | 1.213 | Boiling Point | 489.475ºC at 760 mmHg |
|---|
| Molecular Formula | C18H21NO6 | Melting Point | / |
|---|
| MSDS | / | Flash Point | 193.208ºC |
|---|
Names
| Name | naproxcinod |
|---|
| Synonym | More Synonyms |
|---|
Naproxcinod BiologicalActivity
| Description | Naproxcinod (Nitronaproxen) is the first in class of cyclooxygenase (COX)-inhibiting nitric oxide donators (CINODs). Naproxcinod shows analgesic and anti-inflammatory effects, it can be used for the research of osteoarthritis and inflammation[1][2][3]. |
|---|
| Related Catalog | Signaling Pathways >>Others >>OthersResearch Areas >>Inflammation/Immunology |
|---|
| In Vitro | Naproxcinod (1-30 μM; 15 min) concentration-dependently increases cGMP level up to 27-fold over basal level[1]. Naproxcinod (1-100 μM; 8 h) concentration-dependently increases HO-1 mRNA in endothelial cells[2]. Western Blot Analysis[2] Cell Line: Endothelial and gastric mucosal cell lines Concentration: 30-1000 μM Incubation Time: 8 and 24 hours Result: Increased HO-1 protein levels in endothelial and gastric mucosal cells and increased HO-1mRNA levels in endothelial cells. |
|---|
| In Vivo | Naproxcinod (0-41 mg/kg; p.o. once daily for 42 weeks) shows a significantly higher mean BW (7.3%) than vehicle group and improves skeletal and cardiac disease phenotype in the mouse model of DMD[3]. Animal Model: C57BL/10 mice with Duchenne muscular dystrophy (DMD)[3] Dosage: 0, 10, 21 and 41 mg/kg Administration: Oral gavage; 0-41 mg/kg once daily for 42 weeks Result: Significantly improved fraction shortening and ejection fraction, and reduced inflammation in vivo. |
|---|
| References | [1]. Berndt G, et al. A common pathway of nitric oxide release from AZD3582 and glyceryl trinitrate. Eur J Pharm Sci. 2004 Feb;21(2-3):331-5. [2]. Berndt G, et al. AZD3582 increases heme oxygenase-1 expression and antioxidant activity in vascular endothelial and gastric mucosal cells. Eur J Pharm Sci. 2005 Jun;25(2-3):229-35. [3]. Uaesoontrachoon K, et al. Long-term treatment with naproxcinod significantly improves skeletal and cardiac disease phenotype in the mdx mouse model of dystrophy. Hum Mol Genet. 2014 Jun 15;23(12):3239-49. |
|---|
Chemical & Physical Properties
| Density | 1.213 |
|---|
| Boiling Point | 489.475ºC at 760 mmHg |
|---|
| Molecular Formula | C18H21NO6 |
|---|
| Molecular Weight | 347.36200 |
|---|
| Flash Point | 193.208ºC |
|---|
| Exact Mass | 347.13700 |
|---|
| PSA | 90.58000 |
|---|
| LogP | 4.00680 |
|---|
| InChIKey | AKFJWRDCWYYTIG-ZDUSSCGKSA-N |
|---|
| SMILES | COc1ccc2cc(C(C)C(=O)OCCCCO[N+](=O)[O-])ccc2c1 |
|---|
Synonyms
| Naproxcinod |
| 2-(S)-(6-methoxy-2-naphthyl)-propanoic acid 4-nitroxybutyl ester |
| HCT-3012 |
| 2-(S)-(6-methoxy-2-naphthyl)-propanoic acid nitrooxybutyl ester |
| 4-nitrooxybutyl (2S)-2-(6-methoxynaphthalen-2-yl)propanoate |
| Nitronaproxen |
| 2-(S)-(6-methoxy-2-naphthyl)propanoic acid 4-(nitrooxy)butyl ester |
| AZD-3582 |
| (S)-2-(6-methoxy-2-naphthyl)propionic acid 4-nitrooxybutyl ester |
| naproxen-n-butyl nitrate |
